Susan Xu

Good afternoon, everyone. Welcome to Provectus' 2026 Annual Stockholder Meeting. My name is Susan Xu from Alliance Advisors, and I'll help facilitate today's meeting. We'll just give everyone a moment to join before we get started. But a few quick housekeeping rules. If you can hear us clearly, you're all set on audio. And if you're experiencing any technical difficulties, please try dialing in by phone using the details in your webinar confirmation e-mail. During the formal [Operator Instructions] Please also note that today's meeting is being recorded.

Before we begin, I'd like to note that the statements made during today's meeting may contain forward-looking statements within the meaning of the federal securities laws. These statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially. Participants are encouraged to review the risk factors and forward-looking statement disclaimers contained in the company's filings within SEC.

All right. I think we're ready to get started. Dominic Webster, are you able to hear me? Yes, we're good.

Okay. All right. I will now turn things over to Ed Pershing, Chairman of the Board and Chief Executive Officer of Provectus Pharmaceuticals to call the meeting to order. Ed, the floor is yours.

Edward Pershing
CEO & Executive Chairman of Board

Good afternoon, everyone. Ladies and gentlemen, on behalf of Provectus Biopharmaceuticals, I'd like to extend a very warm welcome to those here in Knoxville as well as those participating online today. Thank you for attending Provectus' 2026 Annual Meeting of Stockholders. I'm Ed Pershing, Chairman of Provectus Board